Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

Omvoh is approved in more than 40 countries for UC and Lilly has also submitted marketing applications for the drug in Crohn's in most major markets, including the EU and Japan. GlobalData has ...

Despite these setbacks, there were some positive takeaways, including a 5% reduction in operating expenses, which could give the company additional flexibility to increase its marketing budget.

Eli Lilly has revealed that subjects with moderately to severely active Crohn's disease have achieved long-term clinical and endoscopic outcomes after two years of continuous treatment with Omvoh ...

In January the company announced that the US Food and Drug Administration had approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is the first ...

The Trump administration is preparing a new executive order that would seek thousands of layoffs at federal health agencies, including the FDA, according to the Wall Street Journal. Citing people ...

We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other ...

UPDATED: Thursday, Jan. 16 at 10:25 a.m. ET Eli Lilly's Omvoh has picked up its second major FDA nod. After the IL-23 inhibitor's approval in 2023 to treat ulcerative colitis, the agency has now ...